Nothing Special   »   [go: up one dir, main page]

BR112013006929A2 - compound of formula I, pharmaceutical composition, process for preparing compounds of formula 9, 16, 20, 27 and 30 - Google Patents

compound of formula I, pharmaceutical composition, process for preparing compounds of formula 9, 16, 20, 27 and 30

Info

Publication number
BR112013006929A2
BR112013006929A2 BR112013006929A BR112013006929A BR112013006929A2 BR 112013006929 A2 BR112013006929 A2 BR 112013006929A2 BR 112013006929 A BR112013006929 A BR 112013006929A BR 112013006929 A BR112013006929 A BR 112013006929A BR 112013006929 A2 BR112013006929 A2 BR 112013006929A2
Authority
BR
Brazil
Prior art keywords
formula
compounds
compound
pharmaceutical composition
relates
Prior art date
Application number
BR112013006929A
Other languages
Portuguese (pt)
Inventor
Abdul Rehman Abdul Rauf
Abhijit Ray
Ian A Cliffe
Jitendra Sattigeri
Manoj Kumar Khera
Neeraj Kumar Yadav
Pradip Kumar Bhatnagar
Punit Srivastava
Sunanda Ghosh Dastidar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR112013006929A2 publication Critical patent/BR112013006929A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/60—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto de fórmula i, composição farmacêutica, processo para preparar os compostos de fórmula 9, 16, 20, 27 e 30. a presente invenção refere-se a certos derivados de ácido sulfona acéticos como inibidor de mmp e processos para sua sintase. a invenção também se refere a composições farmacológicas contendo os compostos da presente invenção e métodos para tratar asma, artrite reumatóide, copd, rinite, osteoartrite, artrite psoriática, psoríase, fibrose pulmonar, inflamação pulmonar, síndrome do desconforto respiratório agudo, periodontite, esclerose múltipla, gengivite, ateroesclerose, secura ocular, proliferação neoíntima que leva a restenose e falha isquêmica cardíaca, derrame, doença renal, metástase tumoral e outros distúrbios inflamatórios caracterizados por superexpressão e superativação de uma matriz de metaloproteinase usando os compostos.compound of formula I, pharmaceutical composition, process for preparing the compounds of formula 9, 16, 20, 27 and 30. The present invention relates to certain acetic sulfone acid derivatives as mmp inhibitor and processes for their synthase. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and methods for treating asthma, rheumatoid arthritis, copd, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis. , gingivitis, atherosclerosis, ocular dryness, neointimal proliferation leading to restenosis and cardiac ischemic failure, stroke, kidney disease, tumor metastasis and other inflammatory disorders characterized by overexpression and overactivation of a metalloproteinase matrix using the compounds.

BR112013006929A 2010-09-24 2011-09-26 compound of formula I, pharmaceutical composition, process for preparing compounds of formula 9, 16, 20, 27 and 30 BR112013006929A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2278DE2010 2010-09-24
PCT/IB2011/054228 WO2012038943A1 (en) 2010-09-24 2011-09-26 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR112013006929A2 true BR112013006929A2 (en) 2016-07-12

Family

ID=44903305

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013006929A BR112013006929A2 (en) 2010-09-24 2011-09-26 compound of formula I, pharmaceutical composition, process for preparing compounds of formula 9, 16, 20, 27 and 30

Country Status (11)

Country Link
EP (1) EP2619177A1 (en)
JP (1) JP2013538820A (en)
KR (1) KR20130137174A (en)
CN (1) CN103221386A (en)
AU (1) AU2011306397A1 (en)
BR (1) BR112013006929A2 (en)
CA (1) CA2812361A1 (en)
EA (1) EA201390405A1 (en)
MX (1) MX2013003360A (en)
SG (1) SG188644A1 (en)
WO (1) WO2012038943A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102154880B1 (en) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. Pharmaceutical nanoparticles showing improved mucosal transport
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN105189462B (en) 2013-02-20 2017-11-10 卡拉制药公司 Therapeutic compound and its purposes
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3700729A1 (en) 1987-01-13 1988-07-21 Boehringer Mannheim Gmbh NEW CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE4111026A1 (en) 1991-04-05 1992-10-08 Boehringer Mannheim Gmbh OPTICALLY ACTIVE CARBONIC ACIDS AND THESE MEDICINAL PRODUCTS
IL164262A0 (en) 2002-04-03 2005-12-18 Novartis Ag 5-Substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as ptpase 1b inhibitors

Also Published As

Publication number Publication date
JP2013538820A (en) 2013-10-17
CA2812361A1 (en) 2012-03-29
KR20130137174A (en) 2013-12-16
EP2619177A1 (en) 2013-07-31
SG188644A1 (en) 2013-05-31
EA201390405A1 (en) 2014-05-30
CN103221386A (en) 2013-07-24
WO2012038943A1 (en) 2012-03-29
AU2011306397A1 (en) 2013-05-02
MX2013003360A (en) 2013-06-05

Similar Documents

Publication Publication Date Title
BR112013006929A2 (en) compound of formula I, pharmaceutical composition, process for preparing compounds of formula 9, 16, 20, 27 and 30
BR112013002370A2 (en) compound, pharmaceutical composition and process for preparing a compound
BR112013006932A2 (en) compound pharmaceutical composition and process for preparing a compound
CU23830B1 (en) INHIBITORS OF THE METALOPROTEINASE MATRIX
BR112012019367A2 (en) heat integration process for ethanol production and purification process.
BRPI0606676A2 (en) processes for the preparation of 4- (phenoxy-5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid derivatives and related compounds
BR112013006118A2 (en) aqueous coating composition and method for preventing oxidation using the aqueous coating composition
BRPI1011506B8 (en) process for manufacturing cystic fibrosis transmembrane conductance regulator modulators
EA200702614A1 (en) METHODS OF OBTAINING 4- (BIPHENYLIL) AZETIDIN-2-ONKYLPHOSPHINE ACIDS
BR112014030674A2 (en) n-aryltriazole compounds as lpar antagonists
BR112012011689A2 (en) process for the production of dabigatran etexilate
ECSP12011910A (en) IMIDAZOPIRIDINE DERIVATIVES AS JAK INHIBITORS
BR112014000471A2 (en) Process for preparing tetrazol substituted anthranilic acid diamide derivatives by reacting pyrazoles with anthranilic esters
IT1401911B1 (en) PROCESS FOR SYNTHESIS OF 2,5-FURANDICARBOSSIC ACID
BRPI0914042A2 (en) process for the production of one or more ethylene amines by a transamination reaction
BR112015006255A2 (en) METHODS FOR THE PRODUCTION OF CHEMICAL PRODUCTS AND DERIVATIVES THEREOF
BR112013030264A2 (en) benzocycloheptene acetic acids
FI20105640L (en) Process for producing microcellulose
CL2011000296A1 (en) Process for preparing 4-oxo-octahydro-indole-1-carboxylic acid methyl ester and intermediate compounds used.
BR112012007635A2 (en) phenyloxadiazole derivatives as pgds inhibitors
CU20100099A7 (en) 5 - [(3,3,3-TRIFLUORO-2-HIDROXI-1-ARILPROPIL) AMINO] -1H-QUINOLIN-2-ONAS, A PROCESS FOR ITS PRODUCTION AND ITS USE AS ANTINFLAMATORY AGENTS
GEP20094786B (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
CU20090009A7 (en) BENCILAMINS, A PROCESS FOR ITS PRODUCTION AND ITS USE AS ANTI-INFLAMMATORY AGENTS
CY1117233T1 (en) PROCEDURE FOR PREVENTION OF NEBIVOLOL
BRPI0907872A2 (en) Process for the production of dicarboxylic acid

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.